Seer 

Yahoo Finance • last month

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature Genetics of a large genome-wide associati... Full story

Yahoo Finance • 2 months ago

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the Human Proteome Organization (HUPO) W... Full story

Yahoo Finance • 2 months ago

Seer Reports Third Quarter 2025 Financial Results

REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025. R... Full story

Yahoo Finance • 3 months ago

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on... Full story

Yahoo Finance • 3 months ago

RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases

APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc.[OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Se... Full story

Yahoo Finance • 3 months ago

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetic... Full story

Yahoo Finance • 5 months ago

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanl... Full story

Yahoo Finance • 5 months ago

Seer reiterates $17M–$18M revenue target for 2025 amid macro headwinds and new Proteograph ONE launch

Earnings Call Insights: Seer, Inc. (SEER) Q2 2025 MANAGEMENT VIEW * Omid C. Farokhzad, Founder, CEO & Chair of the Board, stated Q2 2025 was a pivotal quarter with "discipline, advance key commercial and product milestones and accelera... Full story

Yahoo Finance • 6 months ago

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Ge... Full story

Yahoo Finance • 6 months ago

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 o... Full story

Yahoo Finance • 7 months ago

Seer director Nishar Dipchand sells shares worth $62,935

Nishar Dipchand, a director at Seer, Inc. (NASDAQ:SEER), recently sold 30,253 shares of the company’s Class A common stock. The sale, completed on June 13, 2025, was executed under a Rule 10b5-1 trading plan, which had been adopted by Dipc... Full story

Yahoo Finance • 7 months ago

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce cost... Full story

Yahoo Finance • 8 months ago

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Prot... Full story

Yahoo Finance • 8 months ago

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended Marc... Full story

Yahoo Finance • 11 months ago

Seer to Participate in the TD Cowen 45th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the up... Full story

Yahoo Finance • 11 months ago

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will showcase new findings at t... Full story

Yahoo Finance • 11 months ago

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fo... Full story

Yahoo Finance • 2 years ago

Need To Know: The Consensus Just Cut Its Seer, Inc. (NASDAQ:SEER) Estimates For 2024

One thing we could say about the analysts on Seer, Inc. (NASDAQ:SEER) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Revenue estimates were cut sharply as... Full story

Yahoo Finance • 2 years ago

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the... Full story

Yahoo Finance • 2 years ago

Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500

REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company was selected as “Proteomics Sol... Full story